{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:11:55Z","timestamp":1783469515538,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T00:00:00Z","timestamp":1557964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Sunovion Pharmaceuticals Europe Ltd","award":["Funding for consensus meeting"],"award-info":[{"award-number":["Funding for consensus meeting"]}]},{"name":"Sunovion Pharmaceuticals Europe Ltd","award":["editorial assistance"],"award-info":[{"award-number":["editorial assistance"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s40120-019-0138-z","type":"journal-article","created":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T18:07:37Z","timestamp":1558030057000},"page":"215-230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Practical Guidance on the Use of Lurasidone for the Treatment of Adults with Schizophrenia"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2518-0688","authenticated-orcid":false,"given":"Afzal","family":"Javed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logos","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Pappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"138_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3109\/15622975.2012.696143","volume":"13","author":"A Hasan","year":"2012","unstructured":"Hasan A, Falkai P, Wobrock T, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13:318\u201378.","journal-title":"World J Biol Psychiatry"},{"key":"138_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2012.739708","volume":"14","author":"A Hasan","year":"2013","unstructured":"Hasan A, Falkai P, Wobrock T, et al.; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14:2\u201344.","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl 2","key":"138_CR3","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, et al.; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry. 2004;161[Suppl 2]:1\u201356.","journal-title":"Am J Psychiatry"},{"key":"138_CR4","unstructured":"National Institute for Health and Care Excellence. Clinical Guideline 178. Psychosis and schizophrenia in adults: prevention and management, https:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-35109758952133. 2014. Accessed 24 Apr 2019."},{"key":"138_CR5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881110391123","volume":"25","author":"TR Barnes","year":"2011","unstructured":"Barnes TR, Schizophrenia Consensus Group of British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25:567\u2013620.","journal-title":"J Psychopharmacol."},{"key":"138_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","volume":"30","author":"SJ Cooper","year":"2016","unstructured":"Cooper SJ, Reynolds GP; With expert co-authors (in alphabetical order):, Barnes T, et al. BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol. 2016;30:717\u201348.","journal-title":"J Psychopharmacol"},{"key":"138_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:927\u201342.","journal-title":"Am J Psychiatry"},{"key":"138_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"138_CR9","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079\u201387.","journal-title":"Arch Gen Psychiatry"},{"key":"138_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/mp.2012.47","volume":"17","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012;17:1206\u201327.","journal-title":"Mol Psychiatry"},{"key":"138_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","volume":"37","author":"L Citrome","year":"2017","unstructured":"Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37:138\u201347.","journal-title":"J Clin Psychopharmacol"},{"key":"138_CR12","unstructured":"Sunovion Pharmaceuticals Europe Ltd. Latuda\u00ae summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/medicine\/29125. 2019. Accessed 24 Apr 2019."},{"key":"138_CR13","unstructured":"Sunovion Pharmaceuticals Inc. Latuda\u00ae prescribing information. http:\/\/www.latuda.com\/LatudaPrescribingInformation.pdf. 2018. Accessed 24 Apr 2019."},{"key":"138_CR14","volume-title":"Stahl\u2019s essential pharmacotherapy: neuroscientific basis and practical applications","author":"SM Stahl","year":"2013","unstructured":"Stahl SM. Stahl\u2019s essential pharmacotherapy: neuroscientific basis and practical applications, 4th edn. Cambridge: Cambridge University Press; 2013.","edition":"4"},{"key":"138_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40262-016-0465-5","volume":"56","author":"WM Greenberg","year":"2017","unstructured":"Greenberg WM, Citrome L. Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature. Clin Pharmacokinet. 2017;56:493\u2013503.","journal-title":"Clin Pharmacokinet"},{"key":"138_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.nurt.2008.10.020","volume":"6","author":"DH Kim","year":"2009","unstructured":"Kim DH, Maneen MJ, Stahl SM. Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. Neurotherapeutics. 2009;6:78\u201385.","journal-title":"Neurotherapeutics."},{"key":"138_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757\u201377.","journal-title":"Ther Clin Risk Manag"},{"key":"138_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hup.2338","volume":"28","author":"S Preskorn","year":"2013","unstructured":"Preskorn S, Ereshefsky L, Chiu YY, et al. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28:495\u2013505.","journal-title":"Hum Psychopharmacol"},{"key":"138_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","volume":"225","author":"M Ogasa","year":"2013","unstructured":"Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl). 2013;225:519\u201330.","journal-title":"Psychopharmacology (Berl)"},{"key":"138_CR20","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4088\/JCP.08m04905","volume":"70","author":"M Nakamura","year":"2009","unstructured":"Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70:829\u201336.","journal-title":"J Clin Psychiatry"},{"key":"138_CR21","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","volume":"47","author":"HA Nasrallah","year":"2013","unstructured":"Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatr Res. 2013;47:670\u20137.","journal-title":"J Psychiatr Res"},{"key":"138_CR22","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","volume":"168","author":"HY Meltzer","year":"2011","unstructured":"Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168:957\u201367.","journal-title":"Am J Psychiatry"},{"key":"138_CR23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","volume":"145","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80\u00a0mg\/day and 160\u00a0mg\/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145:101\u20139.","journal-title":"Schizophr Res"},{"key":"138_CR24","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4088\/JCP.12m08084","volume":"74","author":"SM Stahl","year":"2013","unstructured":"Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6\u00a0weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74:507\u201315.","journal-title":"J Clin Psychiatry"},{"key":"138_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","volume":"147","author":"A Loebel","year":"2013","unstructured":"Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res. 2013;147:95\u2013102.","journal-title":"Schizophr Res"},{"key":"138_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0269881115620460","volume":"30","author":"R Tandon","year":"2016","unstructured":"Tandon R, Cucchiaro J, Phillips D, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol. 2016;30:69\u201377.","journal-title":"J Psychopharmacol"},{"key":"138_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","volume":"27","author":"L Citrome","year":"2012","unstructured":"Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27:165\u201376.","journal-title":"Int Clin Psychopharmacol"},{"key":"138_CR28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2147\/NDT.S68417","volume":"11","author":"PD Harvey","year":"2015","unstructured":"Harvey PD. The clinical utility of lurasidone in schizophrenia: patient considerations. Neuropsychiatr Dis Treat. 2015;11:1103\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"138_CR29","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1517\/14656566.2015.1058780","volume":"16","author":"D Bruijnzeel","year":"2015","unstructured":"Bruijnzeel D, Yazdanpanah M, Suryadevara U, et al. Lurasidone in the treatment of schizophrenia: a critical evaluation. Expert Opin Pharmacother. 2015;16:1559\u201365.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl 1","key":"138_CR30","first-page":"20","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68[Suppl 1]:20\u20137.","journal-title":"J Clin Psychiatry"},{"key":"138_CR31","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"13","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;13:2231\u201341.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"138_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.21037\/atm.2018.03.17","volume":"6","author":"WS Aronow","year":"2018","unstructured":"Aronow WS, Shamliyan TA. Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders. Ann Transl Med. 2018;6:147.","journal-title":"Ann Transl Med."},{"key":"138_CR33","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28:421\u201353.","journal-title":"CNS Drugs"},{"key":"138_CR34","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/schbul\/sbv001","volume":"41","author":"MK de Boer","year":"2015","unstructured":"de Boer MK, Castelein S, Wiersma D, et al. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015;41:674\u201386.","journal-title":"Schizophr Bull"},{"key":"138_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/WNF.0000000000000117","volume":"39","author":"E Longden","year":"2016","unstructured":"Longden E, Read J. Assessing and reporting the adverse effects of antipsychotic medication: a systematic review of clinical studies, and prospective, retrospective, and cross-sectional research. Clin Neuropharmacol. 2016;39:29\u201339.","journal-title":"Clin Neuropharmacol"},{"key":"138_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PPA.S124658","volume":"11","author":"DI Velligan","year":"2017","unstructured":"Velligan DI, Sajatovic M, Hatch A, et al. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449\u201368.","journal-title":"Patient Prefer Adherence"},{"key":"138_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2004.09.009","volume":"72","author":"MF Green","year":"2004","unstructured":"Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41\u201351.","journal-title":"Schizophr Res"},{"key":"138_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/schbul\/sbv018","volume":"41","author":"MF Green","year":"2015","unstructured":"Green MF, Llerena K, Kern RS. The \u201cRight Stuff\u201d revisited: what have we learned about the determinants of daily functioning in schizophrenia? Schizophr Bull. 2015;41:781\u20135.","journal-title":"Schizophr Bull"},{"issue":"Suppl 2","key":"138_CR39","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1093\/schbul\/sbr084","volume":"37","author":"KH Nuechterlein","year":"2011","unstructured":"Nuechterlein KH, Subotnik KL, Green MF, et al. Neurocognitive predictors of work outcome in recent-onset schizophrenia. Schizophr Bull. 2011;37(Suppl 2):S33\u201340.","journal-title":"Schizophr Bull"},{"key":"138_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.schres.2011.01.004","volume":"127","author":"PD Harvey","year":"2011","unstructured":"Harvey PD, Ogasa M, Cucchiaro J, et al. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127:188\u201394.","journal-title":"Schizophr Res."},{"key":"138_CR41","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.euroneuro.2013.08.003","volume":"23","author":"PD Harvey","year":"2013","unstructured":"Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23:1373\u201382.","journal-title":"Eur Neuropsychopharmacol"},{"key":"138_CR42","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/03007995.2017.1284656","volume":"33","author":"K Rajagopalan","year":"2017","unstructured":"Rajagopalan K, Wade S, Meyer N, Loebel A. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis. Curr Med Res Opin. 2017;33:813\u201320.","journal-title":"Curr Med Res Opin"},{"key":"138_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/2045125317749740","volume":"8","author":"IJ Osborne","year":"2018","unstructured":"Osborne IJ, Mace S, Taylor D. A prospective year-long follow-up of lurasidone use in clinical practice: factors predicting treatment persistence. Ther Adv Psychopharmacol. 2018;8:117\u201325.","journal-title":"Ther Adv Psychopharmacol."},{"key":"138_CR44","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.4088\/JCP.16m10698","volume":"77","author":"A Loebel","year":"2016","unstructured":"Loebel A, Silva R, Goldman R, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry. 2016;77:1672\u201380.","journal-title":"J Clin Psychiatry"},{"key":"138_CR45","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/ajhp\/54.21.2461","volume":"54","author":"LC Holloman","year":"1997","unstructured":"Holloman LC, Marder SR. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharm. 1997;54:2461\u201377.","journal-title":"Am J Health Syst Pharm"},{"key":"138_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2165\/00002018-200528030-00002","volume":"28","author":"JM Pierre","year":"2005","unstructured":"Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191\u2013208.","journal-title":"Drug Saf"},{"key":"138_CR47","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136.","journal-title":"Br J Psychiatry"},{"key":"138_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1192\/bjp.bp.109.070540","volume":"196","author":"M Poyurovsky","year":"2010","unstructured":"Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010;196:89\u201391.","journal-title":"Br J Psychiatry"},{"key":"138_CR49","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/01.jcp.0000084027.22282.16","volume":"23","author":"M Poyurovsky","year":"2003","unstructured":"Poyurovsky M, Epshtein S, Fuchs C, et al. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol. 2003;23:305\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"138_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/NDT.S9810","volume":"6","author":"LK Hansen","year":"2010","unstructured":"Hansen LK, L\u2019allemand T, Thiry F, et al. Structured relaxation in the treatment of akathisia: case series. Neuropsychiatr Dis Treat. 2010;6:269\u201371.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"138_CR51","volume-title":"The maudsley prescribing guidelines in psychiatry","author":"DM Taylor","year":"2018","unstructured":"Taylor DM, Barnes TRE, Young AH. The maudsley prescribing guidelines in psychiatry, 13th edn. Oxford: Wiley Blackwell; 2018.","edition":"13"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-019-0138-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-019-0138-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-019-0138-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:13:05Z","timestamp":1712329985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-019-0138-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,16]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1007\/s40120-019-0138-z","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,16]]},"assertion":[{"value":"18 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}